Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: XL147 (SAR245408) Clear all
Completed Phase 1Phase 2 Interventional

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

NCT01042925
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
XL147 (SAR245408), trastuzumab, paclitaxel
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • Fort Meyers, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

NCT01013324
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Neoplasms
Interventions
XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Newport Beach, California • Orlando, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

NCT00692640
View directory record Official record
Conditions
Cancer, Non-small Cell Lung Cancer
Interventions
XL147 (SAR245408), Erlotinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 17, 2026, 1:16 AM EDT
Withdrawn Phase 1 Interventional

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

NCT00704392
View directory record Official record
Conditions
Cancer, Non-small-cell Lung Cancer, Breast Cancer
Interventions
XL647, XL147
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

NCT00486135
View directory record Official record
Conditions
Cancer, Lymphoma
Interventions
XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Augusta, Georgia • Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

NCT01587040
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR245408, SAR245409
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

NCT00756847
View directory record Official record
Conditions
Cancer, Non-Small Cell Lung Cancer, Endometrial Carcinoma, Ovarian Carcinoma
Interventions
XL147 (SAR245408),, paclitaxel, carboplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
St Louis, Missouri • Oklahoma City, Oklahoma • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

NCT01240460
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
XL765 (SAR245409), XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

NCT01436565
View directory record Official record
Conditions
Solid Tumor Cancers
Interventions
MM-121 (SAR256212), SAR245408
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • Brookline, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

NCT01082068
View directory record Official record
Conditions
Breast Cancer
Interventions
XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Fort Meyers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 17, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

NCT01357330
View directory record Official record
Conditions
Solid Tumors
Interventions
SAR245408 (XL147), MSC1936369B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 17, 2026, 1:16 AM EDT